Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
COGT
COGT
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
COGT News
Bezuclastinib Shows Significant Clinical Trial Results
Feb 28 2026
Newsfilter
COGENT SECURITY SECURES FUNDING LED BY BAIN CAPITAL VENTURES, WITH CONTRIBUTIONS FROM GREYLOCK PARTNERS AND DEFINITION
Feb 18 2026
moomoo
Rock Springs Capital Reduces Stake in Cogent Biosciences
Feb 17 2026
Fool
First Turn Management Acquires New Position in Cogent Biosciences
Feb 17 2026
Fool
Fairmount Funds Management Sells 3.5 Million Shares of Cogent
Feb 01 2026
NASDAQ.COM
Fairmount Funds Sells 3.5 Million Shares of Cogent Biosciences
Feb 01 2026
Fool
Pfizer Shares Rise on Upgraded Price Forecast
Jan 27 2026
Benzinga
Cogent Biosciences Receives FDA Breakthrough Therapy Designation
Jan 26 2026
Benzinga
Cogent Biosciences Insider Sells 65,000 Shares for $2.52 Million
Jan 11 2026
NASDAQ.COM
Cogent Biosciences' CLO Sells 65,000 Shares for $2.52 Million
Jan 11 2026
Fool
Cogent Biosciences Shares Surge in 2025 Amid Executive Stock Sales
Jan 02 2026
Barron's
Palvella Therapeutics Stock Soars to $114.69 Following Pipeline Developments
Dec 31 2025
NASDAQ.COM
Cogent Submits NDA for Bezuclastinib in NonAdvanced Systemic Mastocytosis
Dec 30 2025
Globenewswire
Cogent Biosciences Submits NDA for Bezuclastinib in NonAdvanced Systemic Mastocytosis
Dec 30 2025
Newsfilter
Analyzing the Best-Performing Russell 2000 Stocks in Relation to the Zacks Rank
Dec 12 2025
NASDAQ.COM
Cogent Biosciences (COGT) Price Target Raised by 10.58% to $48.13
Dec 07 2025
NASDAQ.COM
Show More News
